Boule Diagnostics – Invitation to presentation of the interim report Q3 2023

Boule Diagnostics AB will publish the interim report for the period January–September 2023 at 07:30, Thursday, November 9^th, 2023. Following the publication, Boule will hold a Teams Live Event at 10:00 for media and investors.

CEO Jesper Söderqvist and CFO Jan Benjaminson will present and comment on the interim report. After the presentation there will be time for audience questions. The presentation will be held in English.

The interim report will be accessible at https://www.boule.com when published.

Please feel free to attend this event!

Time:   10.00 CET, Thursday, November 9^th, 2023

Please follow this link to attend!

For more information, please contact:
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90
Jan Benjaminson, CFO, Boule Diagnostics AB, phone +46 (0)70-666 93 88

About Boule Diagnostics AB (publ)
Boule Diagnostics AB (publ) is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies to which it offers complete systems for blood diagnostics (hematology) in both the human and veterinary areas. Boule has strong positions in important emerging markets such as in Asia and in recent years has improved its position in the fast-growing veterinary market. Operations are conducted through operating subsidiaries in Sweden, the United States, Mexico and Russia. The Group reported net sales of SEK 548 million in 2022 and has more than 200 employees. Sales are conducted globally, predominantly through the company’s 200 or so distributors in over 100 countries, supported by Boule’s own local sales and service personnel. Boule has been listed on Nasdaq Stockholm since 2011. www.boule.com

The information was submitted for publication, through the agency of the contact person set out above, at 11:00 CET on November 6, 2023.

Boule Diagnostics - Invitation to the presentation of interim report Q3 2023